Ofloxacin Ophthalmic Solution Recalled Nationwide for Manufacturing Quality Issues
Akorn, Inc. is recalling Ofloxacin Ophthalmic Solution 0.3% due to manufacturing quality deviations. The recall affects 65,006 bottles distributed nationwide.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is a Class II voluntary recall due to manufacturing quality deviations with no reported illnesses or injuries documented in the source. Class II recalls indicate potential for adverse effects but lack reported incidents, fitting the Moderate category for voluntary precautionary recalls.
Plain-English summary
Akorn, Inc. is recalling Ofloxacin Ophthalmic Solution, USP 0.3% in 5 mL bottles (NDC: 13985-602-05) due to deviations from Current Good Manufacturing Practice (CGMP) standards. The recall affects 65,006 bottles that were distributed nationwide in the United States.
This is a Class II voluntary recall initiated by the manufacturer on October 13, 2022, after the firm identified manufacturing deviations in its production processes. The FDA formally classified the recall on January 13, 2023.
Patients currently using this medication should contact their healthcare provider or pharmacist regarding the recall. Do not stop using the medication without medical advice, as this is a prescription product requiring professional guidance. The affected lot numbers are 11B26A (expiration date 1/31/2023) and 1H02A (expiration date 7/31/2023).
Healthcare providers and patients can check the FDA's drug recall database for additional information and updates on this recall.
The recalled product
- Product
- Ofloxacin Ophthalmic Solution, USP 0.3%, 5 mL per bottle, Rx Only, Manufactured by: Akorn, Inc., Lake Forest, IL 60045; Distributed by: MWI, Boise, ID 83705. NDC: 13985-602-05
- Manufacturer
- Akorn, Inc.
- Category
- Drug — Ophthalmic Solution
- Hazard
- cgmp-deviation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Lot: 11B26A
- EXP 1/31/2023
- 1H02A
- EXP 7/31/2023
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27